Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections.
about
Molecular Mechanisms and Clinical Impact of Acquired and Intrinsic Fosfomycin ResistanceResistance development of cystic fibrosis respiratory pathogens when exposed to fosfomycin and tobramycin alone and in combination under aerobic and anaerobic conditions.Low fitness cost of the multidrug resistance gene cfr.Fitness cost of antibiotic susceptibility during bacterial infection.Cationic Peptides Facilitate Iron-induced Mutagenesis in BacteriaExperience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms.Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens.Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists.Fosfomycin: Mechanism and Resistance.Inhaled Antimicrobials for Ventilator-Associated Pneumonia: Practical Aspects.Synergistic activity of fosfomycin, β-lactams and peptidoglycan recycling inhibition against Pseudomonas aeruginosa.Validation of the mutant selection window hypothesis with fosfomycin against Escherichia coli and Pseudomonas aeruginosa: an in vitro and in vivo comparative study.Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development.Frequency of spontaneous resistance to fosfomycin combined with different antibiotics in Pseudomonas aeruginosa.Pharmacokinetic/pharmacodynamic parameters for treatment optimization of infection due to antibiotic resistant bacteria: a summary for practical purposes in children and adults.In vitro activity of antimicrobial combinations against multidrug-resistant Pseudomonas aeruginosa.Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates.Antibiotic resistance and stress in the light of Fisher's model.The Versatile Mutational Resistome of Pseudomonas aeruginosa.
P2860
Q26853135-4D496396-2FE6-44F1-A7CA-778EF69B880EQ34921154-7E1E3C5B-A3A0-4460-A254-8F4C21BCEA69Q35139469-124B8D68-9D05-42BA-9AD2-720D3CA01839Q35707529-0709D353-14DA-4CB4-ADB6-3132CDE627F3Q35796604-9C60E9B6-A441-4A0C-A190-98E1F98E4691Q36364199-808CEF49-F2D1-4B61-96C6-9952447862B5Q37957839-B5AA5361-5530-4ED0-9E4C-80A9F1EA644BQ38208281-3B9DE69B-6F3C-4797-B2E7-D183180D22A5Q39071416-C39CCA80-1114-411E-9726-C333CA52C259Q40121090-8C7690F1-88C9-4D16-9D07-DD25DE0B127FQ40401711-A24DB1F6-DE87-4E77-890E-FD20E342787EQ40499211-F17AFD93-0191-43F5-8A08-1AEC7C9D190DQ40697349-4C6EAAAC-98BB-4D1C-9673-69D884AB1796Q42246515-FD9E1FB4-59C0-4C72-92E5-875129F3528EQ42375984-F2121756-7877-45D3-8FDF-DD3B7539B5E6Q48197188-2E7ABA66-2E27-43FD-B97E-DA2B96D5C0D8Q50792742-BA3CB667-E2F3-40A9-B5DC-6AFB653A974FQ51017942-3E6C29AA-5B92-4B15-98BB-BD66017866F9Q51544118-8951BD83-4F9A-4E34-AB32-3F4594D45382Q52313185-8C1864E2-E84F-4666-BD0D-313AFE933DB1
P2860
Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Assessing the emergence of res ...... for P. aeruginosa infections.
@ast
Assessing the emergence of res ...... for P. aeruginosa infections.
@en
Assessing the emergence of res ...... for P. aeruginosa infections.
@nl
type
label
Assessing the emergence of res ...... for P. aeruginosa infections.
@ast
Assessing the emergence of res ...... for P. aeruginosa infections.
@en
Assessing the emergence of res ...... for P. aeruginosa infections.
@nl
prefLabel
Assessing the emergence of res ...... for P. aeruginosa infections.
@ast
Assessing the emergence of res ...... for P. aeruginosa infections.
@en
Assessing the emergence of res ...... for P. aeruginosa infections.
@nl
P2093
P2860
P1433
P1476
Assessing the emergence of res ...... for P. aeruginosa infections.
@en
P2093
Alexandro Rodríguez-Rojas
Alfredo Castañeda-García
Antonio Oliver
Cristina Gómez
Jesús Blázquez
María D Maciá
P2860
P304
P356
10.1371/JOURNAL.PONE.0010193
P407
P577
2010-04-15T00:00:00Z